Boston, February 13, 2026
Alnylam Pharmaceuticals marks a major milestone by achieving profitability for the first time in its history. With a GAAP net income of $313.75 million and total revenues of $3.7 billion in 2025, this success is driven primarily by the drug Amvuttra. Alnylam has demonstrated the importance of strategic investment in the biotech sector, contributing significantly to Boston’s economy and showcasing the region’s innovation capabilities.
Boston Biotech Pioneer Alnylam Achieves Historic Profitability
After more than two decades of dedicated research and development, Alnylam Pharmaceuticals, a key player in Massachusetts’ vibrant biotechnology sector, has announced its first year of profitability. This significant milestone underscores the power of sustained entrepreneurial vision and private investment in fostering medical innovation and contributing to Boston’s robust economic growth.
The company’s journey to financial success, marked by a GAAP net income in 2025, serves as a compelling narrative for the resilience and long-term commitment often required in the demanding field of biotechnology. It highlights how cutting-edge science, when coupled with strategic business development, can yield substantial benefits for both patients and the regional economy, bolstering Boston MA business prospects.
A Quarter-Century of Innovation Culminates in Profit
Alnylam Pharmaceuticals, a global commercial-stage biopharmaceutical company, reached a significant milestone by achieving profitability for the first time in its 24-year history in 2025. This achievement validates years of strategic investments in research and development and successful product launches, reflecting a commitment to pioneering RNA interference (RNAi) therapeutics. The company reported a GAAP net income of $313.75 million for the full year 2025, a notable shift from a net loss of $278.16 million in 2024.
The total revenues for Alnylam reached $3.7 billion in 2025, marking a 65% increase from 2024. This substantial growth was driven by the strong performance of its key products and strategic initiatives.
Amvuttra Drives Remarkable Revenue Growth
A primary catalyst for Alnylam’s newfound profitability was the exceptional performance of its transthyretin (TTR) franchise, particularly the drug Amvuttra (vutrisiran). Amvuttra, approved in the U.S. for ATTR amyloidosis with cardiomyopathy (ATTR-CM), played a crucial role in driving increased patient demand. Global net product revenues for Amvuttra and Onpattro combined reached $2.3 billion for the full year 2025, representing a 103% growth compared to 2024. Specifically, Amvuttra alone generated $2.3 billion in 2025 revenue. The drug’s approval for both heart and nerve symptoms further solidified its market position.
The TTR franchise, which includes both Amvuttra and Onpattro, generated $858 million in revenue for the fourth quarter of 2025, showing a 151% increase compared to the fourth quarter of 2024. Beyond the TTR franchise, Alnylam’s rare disease segment, including GIVLAARI and OXLUMO, achieved combined revenues of $500 million for the full year 2025, an 18% increase from 2024.
Boston’s Biotech Ecosystem: A Hub for Massachusetts Entrepreneurs
Alnylam’s success is a testament to the thriving biotech ecosystem in Boston and across Massachusetts, a region consistently recognized as a global leader in scientific innovation. The Boston biotech ecosystem has generated significant wealth, created thousands of jobs, and attracted billions of dollars in investment, reinforcing the state’s economic resilience. Approximately 1,000 biotech companies in Greater Boston alone employ over 100,000 people. Massachusetts biotech drew nearly $9 billion in private venture capital and $3.2 billion in National Institutes of Health funding in 2022. By 2024, the state’s biopharma firms raised $7.8 billion in life-science venture capital. The state continues to attract significant venture capital, with Massachusetts companies completing 197 funding rounds in 2025, representing 26.2% of all U.S. biopharma venture capital.
This dynamic environment, fostered by world-class academic institutions like Harvard and MIT, provides a fertile ground for Boston small business growth and large-scale entrepreneurial ventures. The collaborative culture between academia, industry, government, and healthcare institutions facilitates the flow of ideas and resources, driving continuous innovation.
Strategic Vision for Sustainable Economic Growth
Looking ahead, Alnylam has launched its “Alnylam 2030” strategy, focusing on scaling through durable ATTR leadership, long-term sustainable innovation, and exceptional financial results. This strategy includes a commitment to significant investments in research and development to expand its RNAi therapeutics offerings and advance its clinical pipeline. The company also announced an expansion of its manufacturing facility in Norton, Massachusetts, with a $250 million investment, further solidifying its presence and contributing to Massachusetts economic growth.
The ongoing commitment to innovation and expansion by companies like Alnylam ensures that Massachusetts remains at the forefront of drug development, producing approximately 15% of the U.S. drug development pipeline. The success stories of Massachusetts entrepreneurs in biotech continue to inspire confidence and attract further investment into the region.
The Massachusetts Advantage: Talent, Collaboration, and Investment
Boston’s position as a leading biotech hub is attributed to several key factors. The presence of top-tier universities and research institutions provides a steady stream of highly skilled graduates and researchers, ensuring access to talent. This skilled workforce is a critical dimension of the biotech cluster, with Massachusetts employing over 143,000 people across the life sciences sector. The availability of venture capital and funding to support biotech startups is also a crucial element, consistently positioning Massachusetts among the top states nationally in biotech funding.
Furthermore, the region’s long history of medical and scientific research has laid a strong foundation for a thriving biotech industry. This combination of talent, capital, and a supportive ecosystem fosters an environment where innovation can flourish, directly benefiting the Boston MA business community and its residents.
Alnylam Pharmaceuticals’ achievement of profitability after 24 years is a powerful illustration of perseverance, scientific ingenuity, and strategic investment paying dividends. It’s a testament to the enduring spirit of Massachusetts entrepreneurs and the robust environment in Boston that supports such long-term endeavors. As this local pioneer continues to innovate, its success not only benefits its shareholders and patients worldwide but also reinforces Boston’s reputation as a global leader in life sciences, driving continued economic growth and opportunity for the community. Supporting local businesses and staying engaged in Boston’s dynamic economic future is crucial as these companies continue to shape our world.
Frequently Asked Questions
When did Alnylam Pharmaceuticals achieve profitability for the first time?
Alnylam Pharmaceuticals achieved profitability for the first time in 2025.
What was Alnylam’s GAAP net income in 2025?
Alnylam’s GAAP net income for the full year 2025 was $313.75 million.
Which drug primarily drove Alnylam’s revenue growth?
The drug Amvuttra primarily drove Alnylam’s revenue growth.
What were the global net product revenues for Amvuttra and Onpattro in 2025?
Global net product revenues for Amvuttra and Onpattro combined reached $2.3 billion for the full year 2025.
How many biotech companies are in Greater Boston?
Approximately 1,000 biotech companies are in Greater Boston alone.
How many people does the biotech sector employ in Massachusetts?
The biotech sector employs over 143,000 people across Massachusetts.
How much venture capital did Massachusetts biotech draw in 2022?
Massachusetts biotech drew nearly $9 billion in private venture capital in 2022.
What is Alnylam’s long-term strategy?
Alnylam’s long-term strategy, “Alnylam 2030,” focuses on scaling through durable ATTR leadership, long-term sustainable innovation, and exceptional financial results.
Key Highlights of Alnylam Pharmaceuticals’ 2025 Performance
| Feature | Detail |
|---|---|
| Year of First Profitability | 2025 |
| GAAP Net Income (Full Year 2025) | $313.75 million |
| Total Revenues (Full Year 2025) | $3.7 billion |
| Revenue Growth (2025 vs. 2024) | 65% |
| Primary Revenue Driver | Amvuttra (transthyretin franchise) |
| Amvuttra & Onpattro Global Net Product Revenues (Full Year 2025) | $2.3 billion |
| Rare Disease Segment Revenues (Full Year 2025) | $500 million (GIVLAARI and OXLUMO combined) |
| Key Strategic Initiative | “Alnylam 2030” strategy |
Deeper Dive: News & Info About This Topic
HERE Resources
Boston Biotech Shows Resilience Amid Corporate Changes
Massachusetts Secures Key Manufacturing Wins, Fueling Economic Growth
Boston Biotech Ignites Nasdaq Hopes
Boston’s Biotech Future: Alnylam Strengthens Leadership
Trump Proposes Tariffs on Imported Pharmaceuticals
Alnylam’s Amvuttra Receives FDA Approval for ATTR-CM
Author: STAFF HERE BOSTON WRITER
The BOSTON STAFF WRITER represents the experienced team at HEREBoston.com, your go-to source for actionable local news and information in Boston, Suffolk County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Boston Marathon, Head of the Charles Regatta, and Boston Harborfest. Our coverage extends to key organizations like the Greater Boston Chamber of Commerce and Associated Industries of Massachusetts, plus leading businesses in finance, biotech, and insurance that power the local economy such as Fidelity Investments, Biogen, and Liberty Mutual Insurance. As part of the broader HERE network, we provide comprehensive, credible insights into Massachusetts's dynamic landscape.
